Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an eye drops solution for ocular use. It lowers intra‑ocular pressure and is used in the management of open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Monoprost, a prostaglandin analog, is employed in ocular conditions where reduction of intra‑ocular pressure is required.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent development of glaucoma. Secondary glaucoma: helps control pressure when other therapies are insufficient.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation change: gradual darkening of iris color. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: swelling of the central retina. - Paradoxical increase in intra‑ocular pressure. - Ocular infection: signs of bacterial or fungal involvement.

When prescribing or using Monoprost, consider the following safety measures.

Pregnancy: safety not established; use only if benefit outweighs risk. Breastfeeding: unknown excretion; exercise caution. Contact lens wearers: may cause deposits; remove lenses before instillation. Active ocular inflammation: avoid until inflammation resolves. Monitor intra‑ocular pressure regularly: adjust therapy based on readings. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of another prostaglandin analog: duplicate therapy may increase side‑effects. - Simultaneous administration of ocular corticosteroids: may reduce efficacy of pressure lowering.

Moderate Interactions (Monitor Closely):\n- Co‑administration with beta‑blocker eye drops: may cause excessive pressure reduction. - Use with carbonic anhydrase inhibitors: potential additive ocular irritation. - Systemic prostaglandin analogs: may enhance systemic prostaglandin effects.